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Half a century ago, Harry Angelman reported three patients with overlapping clinical features,
now well known as Angelman syndrome. Angelman syndrome is caused by mutations affect-
ing the maternally inherited UBE3A gene, which encodes an E3-ubiquitin ligase that is critical
for typical postnatal brain development. Emerging evidence indicates that UBE3A plays a par-
ticularly important role in the nucleus. However, the critical substrates that are controlled by
UBE3A remain elusive, which hinders the search for effective treatments. Moreover, given
the multitude of signalling mechanisms that are derailed, it is unlikely that targeting a single
pathway is going to be very effective. Therefore, expectations are very high for approaches
that aim to restore UBE3A protein levels. A particular promising strategy is an antisense
oligonucleotide approach, which activates the silenced paternal UBE3A gene. When success-
ful, such treatments potentially offer a disease-modifying therapy for Angelman syndrome
and several other neurodevelopmental disorders.
ANGELMAN SYNDROME: FROM THREE INDIVIDUALS
TO A WELL-CHARACTERIZED SYNDROME
In 1965, the English paediatrician Harry Angelman reported
three patients with severe neurodevelopmental delay and
overlapping features, now well known as Angelman syn-
drome.1 The estimated birth incidence of Angelman syn-
drome is approximately 1 in 20 0002 and it is characterized
by intellectual disability, impaired motor coordination, sei-
zures, characteristic EEG abnormalities, sleep impairments,
increased anxiety, lack of speech, and high comorbidity with
autism spectrum disorder.2 The first clinical manifestations
usually present during the first year of life, when parents
notice the lack of psychomotor activity and seizures.3–5 Cur-
rently, only symptomatic treatments are available for Angel-
man syndrome, which aim to reduce seizures, improve sleep,
or improve behavioural aspects.6
Angelman syndrome is caused by the loss of UBE3A pro-
tein.7 The UBE3A gene lies in the imprinted Angelman syn-
drome/Prader–Willi syndrome 15q11.2-q13 locus, such that
in neurons only the maternally inherited UBE3A gene is
expressed. Four different genetic causes can lead to loss of
functional UBE3A protein in neurons.8 The most common
cause (approximately 70%) represents a de novo deletion of
maternal chromosomal region 15q11.2-q13 encompassing
the UBE3A gene. The second frequent cause is a de novo or
inherited mutation in the maternal UBE3A gene itself, lead-
ing to a loss of functional UBE3A protein. A less frequent
cause is paternal uniparental disomy of chromosome 15,
which results in decreased UBE3A protein levels owing to
two imprinted chromosomes. Similarly, imprinting defects,
due to mutations affecting the Prader–Willi syndrome
Imprinting Center, affect UBE3A protein expression
through repression of the maternal UBE3A gene (Fig. 1).
Some patients with Angelman syndrome-like phenotypes
have been reported who meet (most of) the clinical criteria
for having Angelman syndrome but who do not fall into
these aforementioned four genetic categories. These
patients are typically affected by a mutation in a different
gene, and hence represent a different syndrome.8,9 For
instance, patients with a HERC2 mutation share many clini-
cal features with those who have Angelman syndrome.10
Interestingly, it has been shown that HERC2 is a positive
regulator of UBE3A activity.11 It needs to be determined
whether the genes that are identified in patients with Angel-
man syndrome-like symptoms can also be directly linked to
UBE3A function. Importantly, it should be noted that a
deviation of the typical Angelman syndrome phenotype
does not rule out a bona fide Angelman syndrome mutation.
Recent reports have shown that certain UBE3A gene muta-
tions lead to phenotypes that are milder than typical Angel-
man syndrome, and patients with these do not meet the
clinical criteria for Angelman syndrome.12,13 Given these
recent findings, it would be useful within the field to discuss
whether we should adopt genetic criteria rather than clinical
criteria to define patients as having Angelman syndrome.
MOUSE MODELS PROVIDE INSIGHT INTO UBE3A
FUNCTION
The identification of the UBE3A gene as the causal
gene for Angelman syndrome7 allowed for the
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generation of mouse models of Angelman syndrome to
study its function.14 The UBE3A gene encodes the E3
ubiquitin ligase UBE3A (previously identified as E6-as-
sociated protein [E6-AP]15) which is an enzyme that is
responsible for linking ubiquitin molecules to their tar-
get proteins. This can either result in the degradation
of these target proteins (poly-ubiquitination) or change
the localization or function of target proteins (mono-
ubiquitination).
In humans, the UBE3A gene encodes for three isoforms
that are generated by alternative splicing, such that they
all display unique amino (N) termini.16,17 The two most
abundant human UBE3A isoforms, 1 and 3, make up
more than 95% of human UBE3A protein and are con-
served in nearly all placental animals.17 The human
UBE3A isoform 2 evolved during early primate evolution
and is not found in other mammals.17 Although the sig-
nificance and function of the different UBE3A isoforms
has yet to be revealed, it is clear that the unique N ter-
minus of the isoforms dictates the localization of
UBE3A.17,18 The predominant expression of the nuclear
isoforms in both mice and humans explains the highly
enriched UBE3A staining observed in these neurons.16–20
Notably, the mouse UBE3A isoform 2 (homologous to
human UBE3A isoform 3) that is cytosolic in mice (and
given the sequence conservation, probably in most other
mammals as well) acquired a mutation during late primate
evolution. Hence, in humans and Old World monkeys,
this isoform is primarily targeted to the nucleus.17 The
finding that most UBE3A protein is nuclear could indi-
cate that the critical targets of UBE3A might be nuclear
as well. In support of that, loss of the cytosolic UBE3A
isoform does not result in a discernible phenotype in
mice. In contrast, loss of the major nuclear isoform
results in typical Angelman syndrome phenotypes in mice
and humans, although in humans this is milder than in
typical cases of Angelman syndrome.12,18 Although several
nuclear targets have been identified21 and UBE3A func-
tion has directly been linked to transcription regula-
tion,22–25 it is not clear which nuclear targets are really
critical for Angelman syndrome pathophysiology. This
greatly hinders the search for UBE3A-target-based treat-
ments.
Apart from the nuclear targets that have been identi-
fied, several cytosolic targets have been reported. How-
ever, similar to the nuclear targets, it is unclear what
their relevance is to Angelman syndrome pathophysiol-
ogy.14,21,26 It should be further noted that direct ubiq-
uitination by UBE3A has not been demonstrated for
most of the presumed UBE3A targets. Instead,
increased levels of target protein in Ube3a mice are
often used as an indication that the breakdown of a
protein is UBE3A dependent. But if nuclear UBE3A
plays a direct or indirect role in gene expression,
increased protein levels could also be the result of
transcriptional changes. This cautionary note is well
illustrated by the observation that the most cited target
of UBE3A, the synaptic protein ARC,27 is no longer
considered to be a direct substrate of UBE3A.28,29
Instead, ARC is a target of the ubiquitin ligase
TRIAD3A/RNF21630 and UBE3A probably regulates
ARC at a transcriptional level.29
Several research laboratories have used mouse models of
Angelman syndrome (or sometimes induced pluripotent
stem cells) to identify novel therapeutics to treat Angelman
syndrome. Such therapeutics can be classified into two
major categories: (1) targeted treatments aimed at correct-
ing pathophysiological deficits associated with Angelman










Figure 1: Genetic causes of Angelman syndrome. Representation of the paternal (P) and maternal (M) chromosomes in individuals with Angelman syn-
drome compared with neurotypical individuals. Note that in all cases the maternally inherited UBE3A gene is affected, either by a deletion of the mater-
nal 15q11-13 locus, an intragenic mutation in the UBE3A gene, the inheritance of two copies of the paternal chromosome (uniparental disomy [UPD]),
or by imprinting defects that repress maternal UBE3A expression.
What this paper adds
• Loss of UBE3A affects multiple signalling pathways in the brain.
• Emerging evidence suggests that UBE3A plays a critical role in the cell
nucleus.
• Trials using antisense oligonucleotides to restore UBE3A levels are continu-
ing.
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syndrome; and (2) treatments aimed at restoring the loss of
UBE3A expression in the brain.
TARGETED TREATMENTS FOR
PATHOPHYSIOLOGICAL DEFICITS ASSOCIATED WITH
ANGELMAN SYNDROME
It has been consistently shown that mouse models of
Angelman syndrome show marked changes in synaptic
plasticity and excitatory/inhibitory balance.14 Therefore,
correcting these changes could provide a great target for
treatment. However, over recent years, the view has
emerged that these neuronal changes cannot be attributed
to just a single mechanism. Several mechanisms have been
identified that could underly the changes in neuronal
excitability: for instance, changes in the alpha1 subunit of
Na/K ATPase,31 in small-conductance calcium-activated
potassium channels (SK channels)32 in calcium and volt-
age-dependent big potassium (BK) channels,33 and in
GABA (c-aminobutyric acid) transporter (GAT1) levels.34
Moreover, multiple changes have been observed in sig-
nalling cascades that are indirectly critical to neuronal
function, such as CAMK2,35,36 Ephexin5-EphB,37 neureg-
ulin-ErbB4,38 TrkB-PSD-95,39 ERK,40 mTORC,41 and
dopamine signalling pathways.42–45 These widespread
changes are consistent with the suggestion that UBE3A
probably plays an important global regulatory role, such as
transcriptional regulation and/or by regulating (nuclear)
proteasome activity to which it is strongly attached.14,18,22–
25
In the face of these widespread changes, it is rather sur-
prising that by specifically targeting a single mechanism,
an electrophysiological or even a behavioural rescue could
be observed in most of the aforementioned studies.31–
33,36,38,39,41 It is unclear how these highly specific treat-
ments, which reversed the behavioural phenotypes in
mouse models of Angelman syndrome, can be reconciled
with the notion that so many mechanisms are affected. We
believe that the observed rescue may in part be due to
using underpowered studies in combination with beha-
vioural readouts that are only weakly affected in mice with
Angelman syndrome. The development of a standardized
behavioural test battery of robust phenotypes, and the con-
comitant power analysis for each test, may allow better
drug selection to then be moved to clinical trials.46 For
example, minocycline treatment was successful in a low-
powered study that focused on a limited number of read-
outs.47 However, when tested in the standardized beha-
vioural test battery with a sufficiently high number of mice
with Angelman syndrome, there was no improvement with
minocycline on any of the readouts,46 nor in clinical trials
of patients with Angelman syndrome.48 Similarly, levodopa
treatment did not show an improvement in the Angelman
syndrome mouse behavioural test battery nor in a clinical
trial.46,49
Given that so many molecular mechanisms seem to be
affected, a treatment that acts at a more global level may
ultimately be more successful in a clinical trial. Several
such treatments were successful in Ube3a mice. For some
of these treatments, the precise mechanism targeted in
Angelman syndrome is unclear, and it is conceivable that
they act more generally as cognitive enhancers (e.g.
treatment with reelin,50 ampakines,51 a neurogenesis
stimulator,52 or IGF-2 treatment53). Other drugs target
the excitatory/inhibitory imbalance by the GABA modu-
lators, such as ganaxolone and gabaxadol.34,54 The latter
drug was able to partly correct motor impairments and
anxiety phenotypes in mice with Angelman syndrome.34
But recent data of a randomized, double-blind, placebo-
controlled, phase 3 study (Neptune trial,
NCT04106557), which enrolled 97 patients treated with
gabaxadol (OV101) or placebo, failed to show a change
in the primary endpoint (overall score on the Clinical
Global Impression-Improvement-Angelman syndrome
scale). In addition, secondary outcome measures were not
significantly changed. These disappointing results indicate
that even identifying more broadly acting treatments is
still very difficult.
As a cautionary note of the translational failures, it
should be pointed out that all drug testing in mice to date
has been performed on mouse models of Angelman syn-
drome that specifically lack Ube3a, whereas most trials have
predominantly included patients with 15q11-13Del Angel-
man syndrome lacking the entire (maternally inherited)
15q11-13 gene cluster. The deletion of the additional
genes in this locus may make it more difficult to obtain a
clinical effect of the tested therapies. Hence, some of the
translational failures might be caused by using an inappro-
priate mouse model.14 Developing additional mouse mod-
els of Angelman syndrome that lack the equivalent genes
of the 15q11-13 gene cluster, or using 15q11-13Del Angel-
man syndrome patient-derived induced pluripotent stem
cells,33,55 might circumvent such issues.
TREATMENTS AIMED AT RESTORING UBE3A
EXPRESSION IN THE BRAIN
Undoubtedly, the most promising therapeutic approach for
treating Angelman syndrome aims at restoring UBE3A
expression. Such a therapy would potentially be disease-
modifying and get as close to a cure as possible. There are
two ways to achieve this: either by gene therapy that intro-
duces UBE3A protein into the brain through viral vectors,
or through activation of the imprinted (silenced) paternal
UBE3A allele.
Viral-mediated delivery of UBE3A in the brain was
shown to be partly effective in mice with Angelman syn-
drome.56 However, a major translational challenge will be
to create safe viral vectors with a good biodistribution that
allow UBE3A expression throughout the human brain.
Moreover, getting the correct amount of UBE3A per cell
is very important, as too much could potentially be detri-
mental and may result in autism.57 Last but not least, such
a viral vector would preferably express both dominant
UBE3A isoforms (or possibly all three isoforms), to ensure
that all UBE3A functions are restored.18
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To circumvent these issues, a very elegant approach to
re-express neuronal UBE3A is by activating the dormant
UBE3A gene on the paternally inherited chromosome
(commonly referred to as ‘unsilencing’). In both humans
and mice, the paternally inherited UBE3A allele is silenced
owing to the paternal expression of the long UBE3A-ATS
transcript (>460 kilobases in humans, approximately 1000
kilobases in mice) that runs antisense to the UBE3A
locus.58 Elegant experiments in mice have demonstrated
that this interferes with the expression of the paternally
inherited Ube3a allele59,60 (Fig. 2). Interfering with the
synthesis of the UBE3A-ATS by topoisomerase inhibi-
tors61 or by Cas9-mediated targeting62 induces paternal
UBE3A gene expression, without the risk of inducing too
much UBE3A expression.
Alternatively, the UBE3A-ATS can be targeted by anti-
sense oligonucleotide (ASO) treatment. With this
approach, binding of the ASO to the UBE3A-ATS leads to
RNase-H-mediated cleavage of the ASO-RNA heterodu-
plex, thereby unsilencing the paternal UBE3A gene63
(Fig. 2). ASO treatment would solve most of the limita-
tions associated with viral injection, especially with respect
to controlling the level and the type (isoform) of UBE3A
expression as well as its biodistribution. ASOs are readily
absorbed by neurons, and given the great success of ASO
treatment for spinal muscular atrophy (a motor neuron dis-
order), such a therapy holds great promise for Angelman
syndrome and many other (genetic) neurodevelopmental
disorders.
Despite its great therapeutic promise, ASO treatment of
mice with Angelman syndrome resulted in a rather disap-
pointing lack of improvement of behavioural phenotypes,
despite significant upregulation of UBE3A protein levels in
most areas of the brain.63 These disappointing results may
have resulted from treating the mice when they were adult.
Subsequent studies showed that the critical period for the
full recovery of well-established Angelman syndrome
mouse phenotypes by Ube3a gene reinstatement lies around
birth.64,65 This suggests that UBE3A function is critical
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Figure 2: Mechanism of neuronal UBE3A imprinting and antisense oligonucleotide (ASO)-mediated unsilencing of paternal UBE3A gene expression. (a)
Overview of the UBE3A locus in neurons of an individual with Angelman syndrome with a mutation in the UBE3A gene (indicated with a star). Note that
most patients with Angelman syndrome carry a maternally inherited deletion of the depicted region extending far beyond the Angelman syndrome
Imprinting Center (AS-IC) and the UBE3A gene. (b) Overview of paternal UBE3A expression in the Angelman syndrome condition upon ASO treatment
(orange). Maternally imprinted genes are depicted in grey, the AS-IC is indicated as an empty purple triangle. The lack of a methylated Prader–Willi
syndrome Imprinting Center (PWS-IC; indicated as an empty purple circle) allows for the transcription of the long non-coding SNHG14 gene, also known
as UBE3A-ATS, which is responsible for suppressing paternal UBE3A transcription (red rectangle). The administration of ASOs leads to cleavage of the
UBE3A-ATS transcript, resulting in the unsilencing of the paternal UBE3A gene (depicted by a green rectangle), allowing restoration of synthesis of the
UBE3A protein.
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by the observation that deletion of the Ube3a gene in adult
mice has little effect.66 How this critical period in mice
with Angelman syndrome relates precisely to the optimal
treatment of patients with Angelman syndrome is
unknown, but it is noteworthy that there is no critical per-
iod for restoring hippocampal plasticity.64 Since hippocam-
pal plasticity is often used as a cellular proxy for learning
and memory formation, this would suggest that gene rein-
statement will improve cognitive function, at least to some
extent, at any treatment age.65,66 Another important ques-
tion is whether UBE3A reinstatement is equally beneficial
in patients who carry the 15q11-13 deletion as in those
carrying the UBE3A mutation. Owing to the lack of a
mouse model of 15q11-13 deletion,14 it is difficult to pre-
dict to what extent the effect of losing the additional genes
in this locus is masked by the severe consequence of losing
UBE3A. However, restoring UBE3A in these patients will
probably still significantly improve symptoms.
Since the sequence of the UBE3A-ATS is poorly con-
served between mice and humans, the use of patient-
derived induced pluripotent stem cells67 has been instru-
mental in identifying efficient ASOs that can be used in
the clinic. Currently, two active clinical trials are taking
advantage of the ASO-mediated UBE3A gene reinstate-
ment approach. One trial is sponsored by Hoffmann-La
Roche (molecule RO7248824; NCT04428281) and the
other is sponsored by GeneTX Biotherapeutics (molecule
GTX-102; NCT04259281). A third trial (sponsored by
Ionis/Biogen) is expected to start soon as well. Since ASOs
do not cross the blood–brain barrier, they will need to be
administered through intrathecal injections. It is important
to note that all current studies are phase I trials, primarily
aimed at investigating the safety and tolerability of ASOs,
as well as looking into their pharmacokinetic and pharma-
codynamic properties. The safety and tolerability aspects
are particularly important as these ASOs cannot be tested
in unaffected population norm volunteers, owing to the
risk of inducing levels of UBE3A that are too high. Nota-
bly, all trials make use of different target sequences, as well
as different phosphodiester linkages and sugar modifica-
tions that stabilize the ASO.68 Hence, both in terms of
efficacy (ASO stability and absorption, UBE3A-ATS bind-
ing and breakdown) and (dose-related) side effects, these
trials may have different outcomes. Needless to say, the
results of these ASO trials are eagerly awaited by the fami-
lies and the medical and scientific communities alike. Suc-
cess of these trials would not only transform the lives of
patients with Angelman syndrome and their families, but
could also offer great opportunities for treating many other
genetic neurodevelopmental disorders.
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